Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
44
ERFSF Quote, Financials, Valuation and Earnings
Last price:
$76.99
Seasonality move
:
15.46%
Day range:
$75.41 - $78.43
52-week range:
$48.55 - $86.20
Dividend yield:
1.59%
P/E ratio:
26.81x
P/S ratio:
1.74x
P/B ratio:
63.90x
Volume:
3K
Avg. volume:
4.2K
1-year change:
46.37%
Market cap:
$13.6B
Revenue:
$8.2B
EPS (TTM):
$2.87
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ERFSF
Eurofins Scientific SE
|
-- | -- | -- | -- | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.95% | $31.70 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
ALVO
Alvotech
|
$159.9M | -$0.01 | 52.19% | -81.29% | $18.83 |
|
AUNA
Auna SA
|
$326.1M | $0.20 | 20.77% | 82.77% | $7.20 |
|
PROCF
Sofgen Pharma SA
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ERFSF
Eurofins Scientific SE
|
$76.99 | -- | $13.6B | 26.81x | $0.68 | 1.59% | 1.74x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.50 | $31.70 | $3.8B | 9.83x | $0.00 | 0% | 3.56x |
|
AGEN
Agenus, Inc.
|
$3.18 | $12.33 | $114.9M | -- | $0.00 | 0% | 0.80x |
|
ALVO
Alvotech
|
$3.80 | $18.83 | $1.2B | 16.50x | $0.00 | 0% | 2.09x |
|
AUNA
Auna SA
|
$5.02 | $7.20 | $371.5M | 7.27x | $0.00 | 0% | 0.32x |
|
PROCF
Sofgen Pharma SA
|
$0.02 | -- | $55.8M | -- | $0.00 | 0% | 0.01x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ERFSF
Eurofins Scientific SE
|
43.41% | -0.350 | -- | 1.08x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 3.124 | 1.15% | 3.40x |
|
AGEN
Agenus, Inc.
|
510.35% | 3.128 | 285.06% | 0.03x |
|
ALVO
Alvotech
|
115.99% | 3.523 | 50.24% | 0.54x |
|
AUNA
Auna SA
|
68.8% | 0.758 | 194.28% | 0.70x |
|
PROCF
Sofgen Pharma SA
|
-- | 647.039 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ERFSF
Eurofins Scientific SE
|
-- | -- | 5.27% | 8.55% | -- | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
ALVO
Alvotech
|
$78.7M | $1.2M | 7.33% | -- | 1.05% | -$84M |
|
AUNA
Auna SA
|
$118.6M | $43.8M | 3.64% | 11.53% | 13.85% | $25.8M |
|
PROCF
Sofgen Pharma SA
|
-- | -- | -- | -- | -- | -- |
Eurofins Scientific SE vs. Competitors
-
Which has Higher Returns ERFSF or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Eurofins Scientific SE's net margin of 96.33%. Eurofins Scientific SE's return on equity of 8.55% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital ERFSFEurofins Scientific SE-- -- $9.6B ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About ERFSF or ACAD?
Eurofins Scientific SE has a consensus price target of --, signalling downside risk potential of --. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.70 which suggests that it could grow by 40.89%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Eurofins Scientific SE, analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Eurofins Scientific SE.
Company Buy Ratings Hold Ratings Sell Ratings ERFSFEurofins Scientific SE0 0 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is ERFSF or ACAD More Risky?
Eurofins Scientific SE has a beta of 0.682, which suggesting that the stock is 31.796% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.872%.
-
Which is a Better Dividend Stock ERFSF or ACAD?
Eurofins Scientific SE has a quarterly dividend of $0.68 per share corresponding to a yield of 1.59%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eurofins Scientific SE pays 28.14% of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Eurofins Scientific SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ERFSF or ACAD?
Eurofins Scientific SE quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Eurofins Scientific SE's net income of -- is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Eurofins Scientific SE's price-to-earnings ratio is 26.81x while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eurofins Scientific SE is 1.74x versus 3.56x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERFSFEurofins Scientific SE1.74x 26.81x -- -- ACADACADIA Pharmaceuticals, Inc.3.56x 9.83x $284M $273.6M
-
Which has Higher Returns ERFSF or AGEN?
Agenus, Inc. has a net margin of -- compared to Eurofins Scientific SE's net margin of -116.82%. Eurofins Scientific SE's return on equity of 8.55% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ERFSFEurofins Scientific SE-- -- $9.6B AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About ERFSF or AGEN?
Eurofins Scientific SE has a consensus price target of --, signalling downside risk potential of --. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 287.84%. Given that Agenus, Inc. has higher upside potential than Eurofins Scientific SE, analysts believe Agenus, Inc. is more attractive than Eurofins Scientific SE.
Company Buy Ratings Hold Ratings Sell Ratings ERFSFEurofins Scientific SE0 0 0 AGENAgenus, Inc.2 1 0 -
Is ERFSF or AGEN More Risky?
Eurofins Scientific SE has a beta of 0.682, which suggesting that the stock is 31.796% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.567, suggesting its more volatile than the S&P 500 by 56.664%.
-
Which is a Better Dividend Stock ERFSF or AGEN?
Eurofins Scientific SE has a quarterly dividend of $0.68 per share corresponding to a yield of 1.59%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eurofins Scientific SE pays 28.14% of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend. Eurofins Scientific SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ERFSF or AGEN?
Eurofins Scientific SE quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Eurofins Scientific SE's net income of -- is lower than Agenus, Inc.'s net income of $63.9M. Notably, Eurofins Scientific SE's price-to-earnings ratio is 26.81x while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eurofins Scientific SE is 1.74x versus 0.80x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERFSFEurofins Scientific SE1.74x 26.81x -- -- AGENAgenus, Inc.0.80x -- $30.2M $63.9M
-
Which has Higher Returns ERFSF or ALVO?
Alvotech has a net margin of -- compared to Eurofins Scientific SE's net margin of -4.62%. Eurofins Scientific SE's return on equity of 8.55% beat Alvotech's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ERFSFEurofins Scientific SE-- -- $9.6B ALVOAlvotech69.22% -$0.02 $1.1B -
What do Analysts Say About ERFSF or ALVO?
Eurofins Scientific SE has a consensus price target of --, signalling downside risk potential of --. On the other hand Alvotech has an analysts' consensus of $18.83 which suggests that it could grow by 395.61%. Given that Alvotech has higher upside potential than Eurofins Scientific SE, analysts believe Alvotech is more attractive than Eurofins Scientific SE.
Company Buy Ratings Hold Ratings Sell Ratings ERFSFEurofins Scientific SE0 0 0 ALVOAlvotech3 1 0 -
Is ERFSF or ALVO More Risky?
Eurofins Scientific SE has a beta of 0.682, which suggesting that the stock is 31.796% less volatile than S&P 500. In comparison Alvotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ERFSF or ALVO?
Eurofins Scientific SE has a quarterly dividend of $0.68 per share corresponding to a yield of 1.59%. Alvotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eurofins Scientific SE pays 28.14% of its earnings as a dividend. Alvotech pays out -- of its earnings as a dividend. Eurofins Scientific SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ERFSF or ALVO?
Eurofins Scientific SE quarterly revenues are --, which are smaller than Alvotech quarterly revenues of $113.7M. Eurofins Scientific SE's net income of -- is lower than Alvotech's net income of -$5.3M. Notably, Eurofins Scientific SE's price-to-earnings ratio is 26.81x while Alvotech's PE ratio is 16.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eurofins Scientific SE is 1.74x versus 2.09x for Alvotech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERFSFEurofins Scientific SE1.74x 26.81x -- -- ALVOAlvotech2.09x 16.50x $113.7M -$5.3M
-
Which has Higher Returns ERFSF or AUNA?
Auna SA has a net margin of -- compared to Eurofins Scientific SE's net margin of 4.74%. Eurofins Scientific SE's return on equity of 8.55% beat Auna SA's return on equity of 11.53%.
Company Gross Margin Earnings Per Share Invested Capital ERFSFEurofins Scientific SE-- -- $9.6B AUNAAuna SA37.52% $0.18 $1.6B -
What do Analysts Say About ERFSF or AUNA?
Eurofins Scientific SE has a consensus price target of --, signalling downside risk potential of --. On the other hand Auna SA has an analysts' consensus of $7.20 which suggests that it could grow by 43.43%. Given that Auna SA has higher upside potential than Eurofins Scientific SE, analysts believe Auna SA is more attractive than Eurofins Scientific SE.
Company Buy Ratings Hold Ratings Sell Ratings ERFSFEurofins Scientific SE0 0 0 AUNAAuna SA4 2 0 -
Is ERFSF or AUNA More Risky?
Eurofins Scientific SE has a beta of 0.682, which suggesting that the stock is 31.796% less volatile than S&P 500. In comparison Auna SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ERFSF or AUNA?
Eurofins Scientific SE has a quarterly dividend of $0.68 per share corresponding to a yield of 1.59%. Auna SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eurofins Scientific SE pays 28.14% of its earnings as a dividend. Auna SA pays out -- of its earnings as a dividend. Eurofins Scientific SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ERFSF or AUNA?
Eurofins Scientific SE quarterly revenues are --, which are smaller than Auna SA quarterly revenues of $316.1M. Eurofins Scientific SE's net income of -- is lower than Auna SA's net income of $15M. Notably, Eurofins Scientific SE's price-to-earnings ratio is 26.81x while Auna SA's PE ratio is 7.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eurofins Scientific SE is 1.74x versus 0.32x for Auna SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERFSFEurofins Scientific SE1.74x 26.81x -- -- AUNAAuna SA0.32x 7.27x $316.1M $15M
-
Which has Higher Returns ERFSF or PROCF?
Sofgen Pharma SA has a net margin of -- compared to Eurofins Scientific SE's net margin of --. Eurofins Scientific SE's return on equity of 8.55% beat Sofgen Pharma SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ERFSFEurofins Scientific SE-- -- $9.6B PROCFSofgen Pharma SA-- -- -- -
What do Analysts Say About ERFSF or PROCF?
Eurofins Scientific SE has a consensus price target of --, signalling downside risk potential of --. On the other hand Sofgen Pharma SA has an analysts' consensus of -- which suggests that it could grow by 20561.16%. Given that Sofgen Pharma SA has higher upside potential than Eurofins Scientific SE, analysts believe Sofgen Pharma SA is more attractive than Eurofins Scientific SE.
Company Buy Ratings Hold Ratings Sell Ratings ERFSFEurofins Scientific SE0 0 0 PROCFSofgen Pharma SA0 0 0 -
Is ERFSF or PROCF More Risky?
Eurofins Scientific SE has a beta of 0.682, which suggesting that the stock is 31.796% less volatile than S&P 500. In comparison Sofgen Pharma SA has a beta of 63.524, suggesting its more volatile than the S&P 500 by 6252.39%.
-
Which is a Better Dividend Stock ERFSF or PROCF?
Eurofins Scientific SE has a quarterly dividend of $0.68 per share corresponding to a yield of 1.59%. Sofgen Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eurofins Scientific SE pays 28.14% of its earnings as a dividend. Sofgen Pharma SA pays out -- of its earnings as a dividend. Eurofins Scientific SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ERFSF or PROCF?
Eurofins Scientific SE quarterly revenues are --, which are smaller than Sofgen Pharma SA quarterly revenues of --. Eurofins Scientific SE's net income of -- is lower than Sofgen Pharma SA's net income of --. Notably, Eurofins Scientific SE's price-to-earnings ratio is 26.81x while Sofgen Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eurofins Scientific SE is 1.74x versus 0.01x for Sofgen Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERFSFEurofins Scientific SE1.74x 26.81x -- -- PROCFSofgen Pharma SA0.01x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
46
ZD alert for Mar 4
Ziff Davis, Inc. [ZD] is up 47.98% over the past day.
Buy
54
KORU alert for Mar 4
Direxion Daily MSCI South Korea Bull 3X Shares [KORU] is down 31.47% over the past day.
Sell
40
PSIX alert for Mar 4
Power Solutions International, Inc. [PSIX] is down 28.97% over the past day.
